Editor’s Note: This article was published in Pharmaceutical Technology Europe’s June 2021 print issue.
Divest and Conquer? GSK's Future is in Question
GSK’s position is raising concerns as it continues working towards its separation of businesses.
Recent news of GlaxoSmithKline’s (GSK’s) sale of its entire stake in Innoviva (1), its respiratory drug partner, indicates the company’s momentum to split into two by 2022 is on track. This type of divestiture is certainly not uncommon in the bio/pharma world—with recent news including Takeda and Tejin Pharma’s transaction for diabetes products (2), and Lonza’s divestiture of its specialty ingredients business (3)—as streamlining operations allows companies to focus on strategic priorities in a fast-moving industry.
Yet, concerns are being raised around GSK’s future, as the company has struggled in the COVID-19 pandemic landscape and has seen its revenues dip in the first quarter of 2021. Additionally, a floundering pipeline and the arrival of activist investor, Elliott Management, taking a major stake in the company are placing more fuel on the fire that the company is under the cosh.
The news isn’t all bad, however, as the European Medicines Agency concluded that sotrovimab—a monoclonal antibody being developed by GSK and Vir Biotechnology—can be used as a treatment for patients with COVID-19 (4). Furthermore, positive clinical trial results have been reported for GSK and Sanofi’s COVID-19 vaccine (5), as well as for Medicago’s COVID-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant (6). So, a potential Europe-wide use of sotrovimab and COVID-19 vaccine developments further down the line will surely boost the company’s reputation and stock price.
References
1. GSK, “GSK Announces Sale of Stake in Innoviva Inc.,” Press Release, 20 May 2021.
2. Takeda, “Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited,” Press Release, 26 Feb. 2021.
3. Lonza, “Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven,” Press Release, 8 Feb. 2021.
4. EMA, “EMA Issues Advice on Use of Sotrovimab (VIR-7831) for Treating COVID-19,” Press Release, 21 May 2021.
5. GSK, “Sanofi and GSK COVID-19 Vaccine Candidate Demonstrates Strong Immune Responses Across All Adult Age Groups in Phase II Trial,” Press Release, 17 May 2021.
6. GSK, “Medicago and GSK Announce Positive Interim Phase II Results of Adjuvanted COVID-19 Vaccine Candidate,” Press Release, 18 May 2021.
About the Author
Felicity Thomas is the European editor for Pharmaceutical Technology Group.
Article Details
Pharmaceutical Technology Europe
Vol. 33, No. 6
June 2021
Page: 6
Citation
When referring to this article, please cite it as F. Thomas, “Divest and Conquer?” Pharmaceutical Technology Europe 33 (6) 2021.
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023Podcast
In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Article
Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
